Influence of intratumoral expression of thymidylate synthase on survival of patients with pancreatic cancer on adjuvant gemcitabine and tegafur regimen

Authors

  • А. I. Dronov O. Bohomolets National Medical University
  • S. V. Zemskov O. Bohomolets National Medical University
  • N. N. Melnyk Ohmatdyt National Children’s Specialized Hospital “ОHMATDET”

DOI:

https://doi.org/10.11603/2414-4533.2016.4.7196

Abstract

Pancreatic cancer (PC) is one of 4 cancers with the highest mortality. Fluorpyrimidine and gemcitabine combination is well known and effective in palliative chemotherapy in PC. Much less frequent the combination is used in adjuvant setting, though it was shown to influence long term survival. However, the effect varies in patients with different tumor phenotype. The purpose of our study is to investigate the association between  intratumoral thymidylate synthase (TS) level and overall survival of patients with PC treated with gemcitabine and tegafur (GemTeg) in adjuvant setting. 62 radically resected patients with PC are involved in the study. Adjuvant GemTeg chemotherapy started not earlier then 2 weeks postoperatively. Ductal adenocarcinoma of the pancreas was verified histologically in all cases. Afterwords TS expression was evaluated immunohistochemically. Kaplan-Meyer curves and log-rank test were used to evaluate the survival. Median survival in patients with high TS expression was 14 months longer than in patients with low TS expression (36 vs 12). The survival benefit in patients with high TS was statistically considerable (p=0.005). High intratumoral level of TS in PC may positively influence prognosis of patients treated by GemTeg in adjuvant setting.

References

Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials / D. Ciliberto, C. Botta, P. Correale [et al.] // Eur. J. Cancer. – 2013. – Vol. 49. – P. 593–603.

Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma / Y. Murakami, K. Uemura, T. Sudo [et al.] // Am. J. Surg. – 2008. – Vol. 195. – P. 757–762.

Combined Analysis of Dihydropyrimidine Dehydrogenase and Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Pancreatic Carcinoma Patients Treated with Adjuvant Gemcitabine Plus S-1 Chemotherapy after Surgical Resection / N. Kondo, Y. Murakami, K. Uemura [et al.] // Ann. Surg. Oncol. – 2012. – Vol. 19. – P. 646–655

Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis / Y. Zhu, M. Qi, L. Lao [et al.] // Genet. Test. Mol. Biomarkers. – 2014. – Vol. 18(5). – P. 306–312.

Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody / S. Ormanns, V. Heinemann, M. Raponi [et al.] // European Journal of Cancer. – Vol. 50, Issue 11. – P. 1891–1899.

H. Purkalne. Terapyya tehafurom v kombynatsyy s oksalyplatynom (TegOX) dlya patsyentov s metastatycheskym kolorektalʹnym rakom / H. Purkalne, V. Kozyrovskys, A. Herynya-Berzynya // Latvijas rsts. – 2016. – 1. – P. 46–47.

Ivanetich K. M. Bifunctional thymidylate synthase-dihydrofolate reductase in protozoa / K. M. Ivanetich, D. V. Santi // FASEB J. – 1990. – Vol. 4. – P. 1591–1597.

Crystallization of human thymidylate synthase / C. A. Schif¬fer, V. J. Davisson, D. V. Santi, R. M. Stroud // J. Mol. Biol. – 1991. – Vol. 219. – P. 161–163.

Thymidylate synthase inhibition in malignant tumors and nor¬mal liver of patients given intravenous 5-fluorouracil / S. P. Spe¬ars, B. G. Gustavsson, M. S. Mitchell [et al.] // Cancer Res. – 1984. – Vol. 44. – P. 4144–4150.

Thymidylate synthase inhibition after administration of fluo¬rouracil with or without leucovorin in colon cancer patients: imp¬lications for treatment with fluorouracil / G. J. Peters, C. L. van der Wilt, C. J. van Groeningen // J. Clin. Oncol. – 1994. – Vol. 12. – P. 2035–2042

Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives / M. Takamura, Y. Nio, K. Yamasawa [et al.] // Anti-Cancer Drugs. – 2002. – Vol. 13. – P. 75–85.

Downloads

Published

2017-02-09

How to Cite

Dronov А. I., Zemskov, S. V., & Melnyk, N. N. (2017). Influence of intratumoral expression of thymidylate synthase on survival of patients with pancreatic cancer on adjuvant gemcitabine and tegafur regimen. Hospital Surgery. Journal Named by L.Ya. Kovalchuk, (4). https://doi.org/10.11603/2414-4533.2016.4.7196

Issue

No. 4 (2016)

Section

EXPERIENCE OF WORK

License

Authors who publish their work in Hospital Surgery. Journal by L. Ya. Kovalchuk agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  
  2. Лицензия Creative Commons
  3. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  4. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)